Business Wire

Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action

Share

There are lawsuits impacting individuals and institutions that entered into over-the-counter financial derivative and non-derivative instruments directly with 17 banks and that received payments tied to U.S. Dollar LIBOR. A Settlement totaling $101 million has been reached with Coöperatieve Rabobank U.A. (“Rabobank”), Lloyds Banking Group plc, Lloyds Bank plc, HBOS plc, and Bank of Scotland plc (together, “Lloyds”), Royal Bank of Canada (“RBC”), and Portigon AG and Westdeutsche Immobilien Servicing AG (together “Portigon”). Earlier settlements totaling $680 million were reached with Barclays, Citibank, Deutsche Bank, HSBC, MUFG, Norinchukin, and SocGen bringing the total settlement amount to $781 million. The remaining Non-Settling Defendants include Bank of America, Credit Suisse, JPMorgan Chase, Royal Bank of Scotland, and UBS.

What does the Settlement provide?

The Settlement will create a Settlement Fund totaling $101 million that will be used to pay eligible Class Members who submit valid claims, as well as attorneys’ fees not to exceed one third of the gross settlement, expenses not to exceed $5,500,000, and service awards to the Class Representatives not to exceed $100,000 per Representative. Additionally, Rabobank, Lloyds, RBC, and Portigon will provide certain cooperation to the Plaintiffs in their ongoing litigation against the Non-Settling Defendants.

Am I eligible to receive a payment from the Settlement?

You are included if you (individual or entity) directly purchased certain U.S. Dollar LIBOR-based instruments from Bank of America, MUFG, Barclays, Citibank, Credit Suisse, Deutsche Bank, HSBC, JPMorgan Chase, Lloyds, Norinchukin, Rabobank, Royal Bank of Canada, Royal Bank of Scotland, Société Générale, UBS, or Portigon (or their subsidiaries or affiliates) in the United States; and owned the instruments at any time between August 2007 and May 2010. The instruments in the Settlement Class include certain interest rate swaps, forward rate agreements, asset swaps, collateralized debt obligations, credit default swaps, inflation swaps, total return swaps, options, and bonds/floating rate notes.

How do I get a payment from the Settlement?

You can submit a Proof of Claim online or by mail. The deadline to submit a Proof of Claim is February 10, 2024. You do not need to submit a Proof of Claim to share in the Settlement if you previously submitted a valid Proof of Claim in the prior settlements and do not seek to modify or supplement your Proof of Claim. You are entitled to receive a payment if you have a qualifying transaction with any of the following banks: Bank of America, MUFG, Barclays, Citibank, Credit Suisse, Deutsche Bank, HSBC, JPMorgan Chase, Lloyds, Norinchukin, Rabobank, Royal Bank of Canada, Royal Bank of Scotland, Société Générale, UBS, or Portigon (or their subsidiaries or affiliates). You do not need to have transacted with Rabobank, Lloyds, RBC, and Portigon specifically. At this time, it is unknown how much each Class Member who submits a valid claim will receive. Visit www.USDollarLiborSettlement.com for more information on submitting a Proof of Claim.

What are my rights?

If you are a member of the Settlement Class and you do not file a timely claim, you will lose your right to receive money or benefits from the $101 million settlement with Rabobank, Lloyds, RBC, and Portigon unless you submitted a valid claim in a prior settlement in the OTC Action. If you would like to retain your right to file your own lawsuit against Rabobank, Lloyds, RBC, and Portigon, you must opt out of the Settlement Class by November 17, 2023. If you stay in the Settlement Class, you may object to the Settlement by November 17, 2023.

The Court’s hearing.

The Court will hold a hearing on December 12, 2023 to consider whether to approve the Settlement and approve Class Counsel’s request of attorneys’ fees of up to one-third of the Settlement Fund, plus reimbursement of costs and expenses and service payments to the Class Representatives. You or your own lawyer may appear and speak at the hearing at your own expense. More information about the Settlement is available on the Settlement website, www.USDollarLiborSettlement.com, and in the Long Form Notice accessible on that website, or by calling 1-888-619-8688.

This notice is only a summary.
For more information, including the full Notice and Settlement Agreement, visit www.USDollarLiborSettlement.com , email info@RabobankLiborSettlement.com , or call 1-888-619-8688

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Susman Godfrey LLP
Seth Ard, 212-471-8354
sard@susmangodfrey.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cirium Ascend Consultancy Lands ‘Appraiser of the Year’ Title for the 10th Time14.1.2025 10:00:00 EET | Press release

Cirium Ascend Consultancy, part of the world’s most trusted source of aviation analytics, Cirium, has once again landed Airline Economics’ prestigious title of ‘Appraiser of the Year’ at an award ceremony last night. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113971776/en/ Cirium awarded 'Appraiser of the Year' (Photo: Business Wire) This marks the tenth win for Cirium Ascend Consultancy, demonstrating its unparalleled expertise within aviation consultancy and underlining its unwavering commitment to excellence, transparency and accuracy. The annual award was presented to Rob Morris, Global Head of Cirium Ascend Consultancy, at the Airline Economics Aviation 100 Global Leaders Awards 2025 in Dublin, Ireland, which celebrates the best companies, individuals and transactions in the aviation finance and leasing sector. 2025’s landmark win makes it the first time a single firm has won the title 10 times, recognising Ciriu

Lincotek Appoints New Group Chief Financial Officer14.1.2025 08:00:00 EET | Press release

Lincotek Group – the global solution provider for the Energy, Aerospace and Medical Device sectors – this week announced the appointment of Vittorio Tavanti as its new Group Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113830801/en/ Vittorio Tavanti - Lincotek new Group Chief Financial Officer (Photo: Business Wire) In addition to his appointment as CFO, Tavanti will also take on an acting role as Chief Information Officer – a new position reflecting the critical part played by technology in Lincotek’s success. Tavanti brings a wealth of experience and a proven track record in driving strategic growth and operational excellence across a variety of businesses over a 20-year career, including Siemens, General Electric Oil & Gas and Baker Huges, as well as Schneider Electric. Most recently, Vittorio held the role of Group Chief Financial Officer – Investor Relator and IT of the Italian stock-exchan

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss14.1.2025 08:00:00 EET | Press release

Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.3,4 Some even find that they appear older than their age.3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth14.1.2025 08:00:00 EET | Press release

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its continued investment in R&D to innovate and advance science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113044812/en/ Almirall HQ in Barcelona (Photo: Business Wire) Almirall combines the strengthening of its growth drivers, particularly the biologics products, with the continued growth of its broad portfolio of medical dermatology solutions, including Klisyri®, Wynzora®, and Seysara®. Almirall’s commercial excellence has been demons

Mesmerise to collaborate with Mayo Clinic to Transform Medical Education and Healthcare Workforce Training14.1.2025 00:10:00 EET | Press release

Mesmerise is proud to announce the creation of NeuRealities, Inc., a transformative company designed to revolutionize medical education and healthcare training. As part of a know-how agreement with Mayo Clinic, the new company seeks to leverage Mayo Clinic’s unparalleled clinical expertise and trusted knowledge with Mesmerise’s pioneering advancements in AI-powered spatial computing to set a new standard for excellence in immersive learning experiences. NeuRealities aims to introduce an open-standards digital platform that redefines how healthcare professionals learn and train. By integrating hyper-realistic AI-enabled digital humans, adaptive immersive experiences, and dynamic content tailored to individual learners, the platform can address critical gaps in medical education. Its first initiative—CT training for radiologic technicians—delivers interactive, hands-on scenarios that simplify complex medical concepts, allowing the potential for training to be more efficient, accessible,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye